These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8192532)

  • 1. Peritoneal dialysis adequacy during the r-Hu EPO treatment.
    Baranowska-Daca E; Ksiazek A
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():51-60. PubMed ID: 8192532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of recombinant human erythropoietin (r-Hu EPO) administration on the blood chemistries and composition in uremic rats.
    Kozioł M; Ksiazek P; Feldo M; Spasiewicz D; Michalak J; Kleinrok Z
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():61-6. PubMed ID: 8192533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin administration improves thiamine content in blood and erythrocytes transketolase activity in pre-dialyzed patients.
    Pietrzak I; Baczyk K; Kubiak W
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():29-37. PubMed ID: 8192530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of subcutaneous recombinant human erythropoietin (r-Hu EPO) in CAPD patients with renal anaemia.
    Janicka L; Ksiazek A; Baranowicz I; Mierzicki P
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():67-77. PubMed ID: 8192534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients.
    Rutkowski B; Debska-Slizień A; Biedunkiewicz B; Bułło B
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():17-21. PubMed ID: 8192528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the nutritional status during treatment of anemia using erythropoietin in patients on regular dialysis therapy].
    Eiselt J; Veselá E; Racek J
    Vnitr Lek; 1994 Jul; 40(7):437-9. PubMed ID: 8073661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
    Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
    Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recombinant human erythropoietin in uremic patients in substitute treatment].
    Canaud B; Mion C
    Rev Prat; 1992 Feb; 42(4):432-40. PubMed ID: 1604162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
    Daschner M; Mehls O; Schaefer F
    Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory mechanisms of erythropoietin levels in dialysis patients.
    Tagawa H; Umezu M; Saito T; Yamakado M; Nagano M; Urabe A; Takaku F
    Nihon Jinzo Gakkai Shi; 1990 Mar; 32(3):297-303. PubMed ID: 2355666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum level of vascular endothelial growth factor is influenced by erythropoietin treatment in peritoneal dialysis patients. (Grupo de Estudios Peritoneales de Madrid).
    del Peso G; Selgas R; Bajo MA; Fernández de Castro M; Aguilera A; Cirugeda A; Jiménez C
    Adv Perit Dial; 2000; 16():85-9. PubMed ID: 11045267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgens for the treatment of anemia in peritoneal dialysis patients.
    Navarro JF; Mora-Fernández C; Rivero A; Macía M; Gallego E; Chahin J; Méndez ML; García J
    Adv Perit Dial; 1998; 14():232-5. PubMed ID: 10649731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The outcome for pediatric patients on peritoneal dialysis.
    Acar B; Yalcinkaya F; Cakar N; Yüksel S; Ozçakar ZB; Uncu N; Kara N; Elhan AH; Ekim M
    J Nephrol; 2008; 21(3):394-9. PubMed ID: 18587728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
    Monnerat C; Leyvraz S
    Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation, peritoneal transport, and response to erythropoietin in peritoneal dialysis patients.
    Pilkey RM; Morton AR; Iliescu EA
    Adv Perit Dial; 2001; 17():153-7. PubMed ID: 11510266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.